Elyxium Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Elyxium Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-152	Closed	-$7.97K	–	403
2025 Q4	$7.97K	Buy	+152	New	+$9.1K	﹤0.01%	808

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Elyxium Wealth's CRSP Position: Q1 2026 in Review

Elyxium Wealth sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 152 shares — an estimated $7.97K sold.

Elyxium Wealth first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $7.97K in Q4 2025. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Elyxium Wealth reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 152 CRISPR Therapeutics shares in Q1 2026, an estimated $7.97K.
Elyxium Wealth first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's CRISPR Therapeutics position peaked at $7.97K in Q4 2025.
492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.